20182017 | 2015 | 2014 | 2013


CTC Screening May Be Effective Method for Preventing Colorectal Cancer

CTC Screening May Be Effective Method for Preventing Colorectal Cancer

Current screening methods have a low sensitivity for precancerous lesions and are inconvenient, leading to high rates of noncompliance.

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors

Survivors assigned to an experimental arm showed an improvement in the FACT-C functional well-being sub-scale from baseline to 12 weeks.

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC

MEK inhibition with cobimetinib may improve the response rate with checkpoint inhibition.

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC

Researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks.

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma

Researchers evaluated whether the PD-1 inhibitor would improve outcomes among patients with HCC who progressed after sorafenib treatment.

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma

Researchers randomly assigned 707 patients with advanced HCC to receive oral cabozantinib 60 mg once daily or placebo.

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer

Preclinical models suggested that PEGPH20, which degrades hyaluronan, would improve survival among patients with metastatic pancreatic adenocarcinoma.

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer

The study arms had similar rates of adverse events, with 34.7% of patients in the cisplatin arm and 31.2% of patients in the S-1 arm reporting clinically relevant events.

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer

Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy may be a lower-cost alternative, with better post-operative outcomes, to open transthoracic esophagectomy.

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Extensive Intraoperative Peritoneal Lavage May Not Improve OS in Gastric Cancer

Previous research suggested that EIPL may improve survival by reducing the number of intraperitoneal-free cancer cells.

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

Aspirin Use Does Not Reduce Risk of Colorectal Cancer Recurrence

There was no evidence that aspirin use beginning at the onset of chemotherapy affected the risk of recurrence among patients with stage II or III colorectal cancer.

Regorafenib Improves Overall Survival in Liver Cancer

Regorafenib Improves Overall Survival in Liver Cancer

Second-line systemic therapy with regorafenib improves overall survival among patients with hepatocellular carcinoma (HCC).

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX Does Not Improve Relapse-free Survival in Biliary Tract Cancer

GEMOX post-surgery adjuvant therapy does not improve relapse-free survival (RFS) among patients with biliary tract cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs